E. Harvey-Jones

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

G. Oades, M. Sullivan, Robert J. Jones, 2016, JAMA oncology.

The impact of national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients

A. Purushotham, R. Sullivan, G. Roberts, 2021, Ecancermedicalscience.

Systemic Therapy for Hereditary Breast Cancers.

A. Tutt, C. Lord, E. Harvey-Jones, 2023, Hematology/oncology clinics of North America.

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

M. Malim, A. Hayday, S. Irshad, 2021, The Lancet Oncology.

New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.

A. Tutt, E. Harvey-Jones, G. Viñas Villaró, 2021, Cancer journal.

Mortality due to cancer treatment delay: systematic review and meta-analysis

W. King, R. Sullivan, C. Booth, 2020, BMJ.

Does Concurrent Use of CDK4/6 Inhibitors During Palliative Radiotherapy Increase Toxicity in Patients With Metastatic Breast Cancer?

A. Swampillai, S. Ahmad, S. Howlett, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines

M. Malim, A. Hayday, S. Irshad, 2021, medRxiv.

Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study

C. Booth, A. Aggarwal, C. Frampton, 2021, European journal of cancer.